New report: CivicaScript saved patients & payers more than $16 million in generic medicine costs in 2025

▤ Summary

CivicaScript says its low-cost generic medicine model saved patients and payer members more than $16 million in 2025. The company reports nearly $44 million in cumulative savings since it launched its first product in 2022. Four specialty generics launched in 2025 and the expansion into biosimilars helped drive the results. The report highlights continued adoption of abiraterone and shows that the company expects savings to keep growing as more therapies gain traction.

▦ Linked Companies